14h
Zacks Investment Research on MSNSynopsys Dips 22% in a Year: Should You Buy, Sell or Hold the Stock?Synopsys Inc. SNPS shares have plunged 22.4% in the past year, underperforming the Zacks Computer and Technology sector and the S&P 500 index’s return of 7.8% and 9.5%, respectively. The stock has ...
Synopsys (SNPS) announced work with NVIDIA (NVDA) to accelerate chip design up to 30x with the NVIDIA Grace Blackwell platform. To achieve this ...
Synopsys’ (SNPS) CEO Sassine Ghazi, recently sold the company’s shares worth $5.37 million. SNPS is a software company that ...
We recently published a list of 10 Tech Stocks with High Upside Potential. In this article, we are going to take a look at where Synopsys, Inc. (NASDAQ:SNPS) stands against other tech stocks with high ...
1d
News-Medical.Net on MSNHigher BMI in adolescence worsens genetic risk for high blood pressure, study findsAdolescent BMI amplifies genetic risk for high blood pressure, with sex-specific differences in how BMI modifies SBP ...
Synopsys and Cadence, beyond EDA software, provide Intellectual Property and collect licensing and royalty fees. Click to ...
About half of these individuals (54 percent) are enrolled in MA Dual-Eligible Special Needs Plans (D-SNPs), specialized MA plans that only enroll dually eligible individuals. Due to higher rates ...
For the quarter ended January 2025, Synopsys (SNPS) reported revenue of $1.46 billion, down 11.8% over the same period last year. EPS came in at $3.03, compared to $3.56 in the year-ago quarter.
Nursing home patients’ enrollment in I-SNPs has been tied to better performance on six of eight major indicators.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results